GSK CEO Emma Walmsley gave an upbeat assessment of the British drugmaker's new respiratory syncytial virus (RSV) vaccine on ...
Federal officials have been working with companies to find ways to boost the supply of the new vaccine for newborns.
As the battle between new respiratory syncytial virus (RSV) vaccines heats up, GSK is “delighted” with the progress it's made ...
Preventive treatment is now available for the respiratory syncytial virus, which affects 64 million people annually. But drug ...
RSV is a common illness among infants. According to experts, 80% of babies catch it within their first year of life.
Pregnant women and their babies and adults over 60 years old can be more protected from respiratory syncytial virus, or RSV, ...
Both shots were approved earlier this year--the first RSV vaccines after decades of unsuccessful attempts--and the third quarter was the first full quarter for which sales were reported. GSK said ...
RSV vaccines are dwindling as cases continue to rise. Here's what you need to know about the RSV vaccine shortage and how you ...
Of the roughly 14,000 doses requested by CT, only about 10,000 have been received and distributed, CT public health officials ...
TAMPA, Fla. - Respiratory syncytial virus, more commonly known as RSV, is a respiratory virus that infects the lungs and breathing passages. It affects all age groups, but can be especially serious ...
Respiratory syncytial virus, or RSV, is a common respiratory virus that spreads seasonally. A new drug and several vaccines that prevent the infection have recently come to market. Here's what you ...
LONDON (Reuters) -GSK CEO Emma Walmsley said on Thursday that the British drugmaker's respiratory syncytial virus (RSV) vaccine was now expected to generate more than 1 billion pounds ($1.26 billion) ...
